INDEPENDENT ANTI-DOPING REFERENCE2026 · CHECKED 08 NOV 2027 PUBLISHED ↗
WADAFUK!?
Source-checked educational research

Ospemifene.

S4
Source-checked educational research

Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.

REGULATORY SUMMARY2026 LIST

Prohibited at all times

2026 S4.2: prohibited at all times. Specified. [1]

S4.2 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.

EVIDENCE / 01

Medical context and formulation

Ospemifene is an oral estrogen agonist/antagonist with tissue-selective effects. The checked US Osphena label treats moderate-to-severe painful intercourse or vaginal dryness due to menopausal vulvar and vaginal atrophy. [2]

Limits of this evidence
  • This is the checked US label, not a worldwide authorization or availability inventory.
EVIDENCE / 02

Selected health warnings

The boxed warning addresses endometrial cancer and cardiovascular disorders. The label also discusses venous thrombosis, abnormal genital bleeding, pregnancy and interacting medicines. Its estrogen-like effect in some tissues means the anti-doping category must not be mistaken for an absence of estrogenic medical effects. [2]

Limits of this evidence
  • The full label and clinician assessment remain necessary; listed risks are not exhaustive.

What remains uncertain

  • No product-specific supplement-contamination pathway was established in this review; a medicine label does not establish contamination prevalence.
TRACEABILITY

Check the sources.

These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.

  1. WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened

    Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable

  2. Osphena ospemifene ↗Accessed 2026-11-10 · Current label highlights and selected full-text sections

    Indications and Usage; formulation; Warnings and Precautions; selected interactions/clinical pharmacology

Before acting on this information

Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.

Something wrong? Prepare a correction draft ↗